drugset / Trial / NCT01738698
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
Timeline
- Start
- 2012-11-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
Outcome
Outcome not reported
Stopped (Business): “Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 40 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 100 mg | Oral |
| Subject | Lisdexamfetamine Dimesylate | Small molecule | 160 mg | Oral |